The type segment is divided into glycopyrrolate tablets and glycopyrrolate solution. The Glycopyrrolate solution segment is expected to strengthen the growth of the type segment in the Glycopyrrolate market. Due to various benefits of the solution segment such as flexible dosing, immediate absorption, and quick response to illness. Moreover, solutions simplify swallowing in difficult situations for patients. This in turn drives the growth of the glycopyrrolate market.
Glycopyrrolate is also known as NVA237 or Glycopyrronium. Glycopyrrolate market is a mixture of long-acting muscarinic antagonists and quaternary ammonium compounds. Glycopyrrolate is one of the commonly prescribed anticholinergic medications and was first granted by FDA on 11 August 1961.
The market is projected to grow at a significant pace reaching a CAGR of approximately XX%, over the forecast period of 2022–2028, despite a considerable fall in Service Operator sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.
The regional segment is divided into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America is expected to contribute a significant revenue share during the forecast period owing to the growing number of patients suffering from peptic ulcers along with rising healthcare expenditure in the region.
The study is consolidated into major segments and further into sub-segments, such as by Type (Glycopyrrolate Tablet, Glycopyrrolate Solution), By Application (Hospital, Clinic), to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Lastly, the report includes a regional analysis and country analysis with the latest trends, along with the major key players including Tai Heng Industry Co. Ltd, Toobapharma, Stellar Chemical Laboratories Pvt., Invent Farma, Suven Life Sciences Limited, Sharon, Infa Group
Contact Us:
